1-3 of 3
JungAh Jung, PhD
Close
Sort by
Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Owen A. O'Connor, MD PhD, Muhit Özcan, MD, Eric D. Jacobsen, MD, Josep Maria Roncero Vidal, MD, Judith Trotman, MBChB, Judit Demeter, MD PhD DsC, Tamás Masszi, MD, Juliana Pereira, MD PhD, Radhakrishnan Ramchandren, MD, Francesco A. d'Amore, MD PhD, Francine Foss, MD, Won-Seog Kim, MD PhD, John P. Leonard, MD, Carlos Sérgio Chiattone, MD PhD, Pier Luigi Zinzani, MD PhD, Hua Liu, PhD, JungAh Jung, PhD, Xiaofei Zhou, PhD, E. Jane Leonard, MSc, Claudio Dansky Ullmann, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2015) 126 (23): 341.
https://doi.org/10.1182/blood.V126.23.341.341
Published: 2015
Journal Articles

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Jonathan Friedberg, MD, Daruka Mahadevan, MD, PhD, JungAh Jung, PhD, Daniel O. Persky, MD, Izidore S Lossos, MD, Hadi Danaee, SD, Xiaofei Zhou, PhD, E Jane Leonard, Steven H. Bernstein
Journal: Blood
Blood (2011) 118 (21): 95.
https://doi.org/10.1182/blood.V118.21.95.95
Published: 2011
Journal Articles

Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Stuart L Goldberg, MD, Pierre Fenaux, MD, PhD, Michael D Craig, MD, Emmanuel Gyan, MD, PhD, John Lister, MD, Jeannine Kassis, MD, Arnaud Pigneux, MD, PhD, Gary J Schiller, MD, JungAh Jung, PhD, E. Jane Leonard, MSc, Howard Fingert, MD, Peter Westervelt, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3273.
https://doi.org/10.1182/blood.V116.21.3273.3273
Published: 2010